In this video, health care analyst David Williamson discusses the recent events around Orexigen Therapeutics, including today's rarely seen price-increasing dilutive offering. Is Orexigen a looming threat to obesity-drug-making heavyweights Arena and VIVUS? Watch and find out.Â
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
A rare positive dilution.
David Williamson has no positions in the stocks mentioned above. Follow him on Twitter @MotleyDavid. The Motley Fool has no positions in the stocks mentioned above. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Related Articles
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week
Is Oscar Health Stock Still a Buy?
Prediction: Wall Street's Latest Stock-Split Stock -- Up 60,120% Year-to-Date -- Is Going to Implode... It's Just a Matter of Time
1 Undervalued Growth Stock That Could Go Parabolic Soon
Why Scholar Rock Shares Are Soaring Today
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.